Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Enhanced outcomes for pediatric patients with de novo chronic myeloid leukemia in blast Phase through early allogeneic stem cell transplantation and tyrosine kinase inhibitor

View Full Paper
Ask AI
Bookmark
Share

Authors

YWYang WanYGYe Guo

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows improved outcomes in pediatric patients with chronic myeloid leukemia, indicating a benefit of early stem cell transplantation combined with tyrosine kinase inhibitors.

Key Points

  • All patients achieved minimal residual disease negativity before hematopoietic stem cell transplantation.
  • Dasatinib and olverembatinib were key tyrosine kinase inhibitors for managing chronic myeloid leukemia post-transplant.
  • Graft-versus-host disease developed in only two patients, which was manageable without serious infections.
  • Unrelated cord blood transplantation emerged as a feasible strategy for pediatric chronic myeloid leukemia cases.

Cite This Study

Wan et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dd0ahttps://doi.org/10.1182/blood-2025-7833
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical outcomes of allogeneic cell transplantation for patients with chronic myeloid leukemia2025
  2. 2[How I treat pediatric chronic myeloid leukemia].2025
  3. 3Clinical characteristics and prognostic factors in myeloid blast-Phase chronic myeloid leukemia2025
  4. 4Long-term outcomes of CML patients undergoing hematopoietic stem cell transplantation in the era of tyrosine kinase inhibitors2025
  5. 5Outcomes of pediatric patients transplanted for B-ALL with high-risk cytogenetics- a 20-year experience from LMIC setting2025